Theravance, Inc., a biopharmaceutical company, engages in the
discovery, development, and commercialization of small molecule
medicines primarily for therapeutic areas of respiratory diseases,
bacterial infections, and central nervous system (CNS)/pain. The company
offers VIBATIV, a bactericidal injectable antibiotic for the treatment
of Gram-positive infections. Its principal development programs with
GlaxoSmithKline plc include the RELOVAIR that has completed Phase 3
clinical studies for the treatment of patients with chronic obstructive
pulmonary disease (COPD) or asthma; the LAMA/LABA combination, a Phase 3
program for patients with COPD; and the Bifunctional Muscarinic
Antagonist-Beta2 Agonist (MABA) program that has completed Phase 2b
study for the treatment of COPD. The company's principal development
programs also comprise and the Peripheral Mu-Opioid Receptor Antagonist
(PµMA) program for the TD-1211 mu-opioid receptor designed to alleviate
gastrointestinal side effects of opioid therapy without affecting
analgesia. In addition, it develops TD-4208 that has completed Phase 2a
single-dose COPD study; TD-1792, an antibiotic under clinical-stage for
the treatment of serious infections caused by Gram-positive bacteria.
The company was formerly known as Advanced Medicine, Inc. and changed
its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded
in 1996 and is headquartered in South San Francisco, California.
To analyze Theravance's stock for potential trading opportunities,
please take a look at the 1-year chart of THRX (Theravance, Inc.) below
with my added notations:
The main price level to watch on THRX is $24 (navy). Not only is the
$24 resistance apparent in April and January, but that price also acted
as support back in the fall. So, the $24 level is key to this stock at
this point. In addition, THRX has a lower level of support at $20 (red).
The Tale of the Tape: THRX has key price level at $24. A long
position could be entered at the $24 support with a stop placed below
that level, or a short trade could be placed on a break below $24, if
that should happen, with an expectation of a fall to $20.
Please bookmark us
No comments:
Post a Comment